Adebrelimab Explained

Type:mab
Mab Type:mab
Source:zu/o
Target:PD-L1
Class:Antineoplastic agent
Atc Prefix:L01
Atc Suffix:FF05
Legal Status:Rx in China
Cas Number:2247114-85-6
Pubchemsubstance:472411821
Unii:1XBY50W1OX

Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.[1] [2]

In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer.[3]

Notes and References

  1. Gan Y, Shi F, Zhu H, Han S, Li D . Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing . Frontiers in Pharmacology . 14 . 1241130 . 2023 . 37547339 . 10398383 . 10.3389/fphar.2023.1241130 . free .
  2. Web site: Adebrelimab - Atridia. AdisInsight . Springer Nature Switzerland AG .
  3. Web site: New drugs approved by NMPA in 2023 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Adebrelimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.